# UNIVERSITY OF COPENHAGEN

# Off-Line High-pH Reversed-Phase Fractionation for In-Depth Phosphoproteomics

Batth, Tanveer S; Francavilla, Chiara; Olsen, Jesper V

Published in: Journal of Proteome Research

DOI: 10.1021/pr500893m

Publication date: 2014

Document version Publisher's PDF, also known as Version of record

Document license: CC BY

*Citation for published version (APA):* Batth, T. S., Francavilla, C., & Olsen, J. V. (2014). Off-Line High-pH Reversed-Phase Fractionation for In-Depth Phosphoproteomics. *Journal of Proteome Research*, *13*(12), 6176-86. https://doi.org/10.1021/pr500893m This is an open access article published under a Creative Commons Attribution (CC-BY) <u>License</u>, which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

# Journal of **proteome**-• research

# Off-Line High-pH Reversed-Phase Fractionation for In-Depth Phosphoproteomics

Tanveer S. Batth, Chiara Francavilla, and Jesper V. Olsen\*

Proteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Science, University of Copenhagen, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark

**Supporting Information** 



**ABSTRACT:** Protein phosphorylation is an important post-translational modification (PTM) involved in embryonic development, adult homeostasis, and disease. Over the past decade, several advances have been made in liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based technologies to identify thousands of phosphorylation sites. However, in-depth phosphoproteomics often require off-line enrichment and fractionation techniques. In this study, we provide a detailed analysis of the physicochemical characteristics of phosphopeptides, which have been fractionated by off-line high-pH chromatography (HpH) before subsequent titanium dioxide (TiO<sub>2</sub>) enrichment and LC-MS/MS analysis. Our results demonstrate that HpH is superior to standard strong-cation exchange (SCX) fractionation in the total number of phosphopeptides detected when analyzing the same number of fractions by identical LC-MS/MS gradients. From 14 HpH fractions, we routinely identified over 30 000 unique phosphopeptide variants, which is more than twice the number of that obtained from SCX fractionation. HpH chromatography displayed an exceptional ability to fractionate singly phosphorylated peptides, with minor benefits for doubly phosphorylated peptides over that with SCX. Further optimizations in the pooling and concatenation strategy increased the total number of multiphosphorylated peptides detected after HpH fractionation. In conclusion, we provide a basic framework and resource for performing in-depth phosphoproteome studies utilizing off-line basic reversed-phased fractionation. Raw data is available at ProteomeXchange (PXD001404).

**KEYWORDS:** Phosphoproteomics, high-pH reversed-phase, phosphorylation, peptides, enrichment, fractionation, titanium dioxide, Orbitrap

## INTRODUCTION

Great advances have been made in the field of biomedical science due to the availability of large-scale proteomics data sets arising from high-performance liquid chromatography—tandem mass spectrometry (LC—MS/MS) experiments. Along with the capability to identify and quantify peptides and proteins by shotgun proteomics, it is also possibly to analyze and localize post-translational modifications (PTMs) to their respective sites.<sup>1</sup> Protein phosphorylation, which mainly modifies Ser, Thr, and Tyr residues in eukaryotes, is of particularly great interest due to its pivotal role in the regulation of several cellular responses and is therefore one of the most widely studied PTMs. Site-specific and dynamic phosphorylation is believed to control virtually all intracellular signaling cascades, thereby

orchestrating the tight regulation of cell proliferation, differentiation, and survival.  $^{\rm 2}$ 

Developments in high-resolution mass spectrometry (MS), computational proteomics, and specific methods for phosphopeptide enrichment have facilitated identification of large number of phosphorylation sites<sup>1</sup> from whole-cell lysates. By enriching phosphopeptide samples prior to nanoscale reversed-phase  $C_{18}$  LC-MS/MS acquisition, it is now possible to analyze thousands of phosphorylation sites in single experiments.<sup>3,4</sup> Despite these developments, difficulties remain in exploring the extent of the phosphoproteome with high depth and reproducibility. Peptide separation strategies have been

Received: August 27, 2014 Published: October 22, 2014

#### Journal of Proteome Research

developed to address some of these issues by reducing sample complexity. Several off- and on-line peptide fractionation methods, such as ion exchange chromatography (IEC), hydrophilic interaction chromatography (HILIC), and electrostatic repulsion-hydrophilic interaction chromatography (ERLIC), have been described to increase the depth of the proteome as well as the number of PTMs analyzed.<sup>5-8</sup> Off-line separation methods are commonly utilized in large-scale PTM analyses due to the ease of implementation and the ability to use large amounts of starting material. Ion exchange chromatography remains the method of choice for peptide fractionation due to the availability of several different column types and its well-characterized separation properties that are orthogonal to those of reversed-phase chromatography. Charged-based separation, such as strong cation exchange (SCX) chromatography, is well-suited for enrichment of phosphopeptides from a population of unmodified tryptic peptides due to the negative charges of the phosphoryl group. For these reasons, SCX (as well has HILIC) chromatography in combination with TiO2/IMAC has, so far, been the most widely used off-line fractionation strategy applied in large-scale phosphoproteomics studies.<sup>10–15</sup> However, fractionation methods based on hydrophobic interactions, such as reversed-phase chromatography, are more efficient for the separation of peptides compared to that of charge-based separations like SCX. Off-line peptide fractionation based on a basic reversedphase (HpH) approach prior to LC-MS/MS analysis has shown great promise in recent years.<sup>16,17</sup> This is due to its highresolving power based on hydrophobic interactions and the use of concatenation strategies of pooling fractions from different parts of the gradient when running at high pH.<sup>17</sup> This is highly orthogonal with the downstream phosphopeptide enrichment and LC-MS/MS analysis using low-pH reversed-phase chromatography in-line with the mass spectrometer. However, so far, only a limited number of studies have assessed the impact on global phosphoproteome coverage with prior fractionation based on hydrophobic interactions.<sup>18</sup> This study provides the first insights into phosphopeptide fractionation by HpH; however, this was performed using a sophisticated online 3D fractionation platform inaccessible to most users.<sup>1</sup> Here, we show a thorough analysis of phosphoproteome coverage with standard off-line high-pH reversed-phase fractionation (HpH) prior to phosphopeptide enrichment and MS analysis.

#### EXPERIMENTAL PROCEDURES

#### NIH-3T3 Culture and Lysis

NIH-3T3 cells were grown in DMEM (Gibco, Invitrogen, Denmark) with 50 U/mL penicillin, streptomycin, and 4 mM glutamine and with the addition of 10% newborn calf serum (NBCS, Gibco, Invitrogen, Denmark). Cell cultures were grown to 60–80% confluence on 245 mm<sup>2</sup> polystyrene Petri dishes and then serum starved overnight in DMEM without serum. The following day, cells were serum-stimulated for 10 min with DMEM containing 10% NBCS for 10 min. Immediately following stimulation, the media was decanted, and the cells were washed with ice cold 1× PBS. Briefly, cold RIPA buffer (1% NP-40, 0.1% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, and 50 mM Tris, pH 7.6) supplemented with 50 mM sodium flouride (NaF), 10 mM sodium orthoranadate, 50 mM  $\beta$ -glycerol phosphate, and 1 protease inhibitor cocktail tablet (Roche, Basil, Switzerland) was added to each 245 mm<sup>2</sup>

plate, which was placed on a shaker at 4 °C for 20–30 min. Cells were scrapped and collected along with remaining buffer into falcon tubes. Tubes were then centrifuged for 25 min at 7197g (4 °C). Protein in the supernatant was acetone-precipitated with four excess volumes of ice-cold acetone and stored at -20 °C until further processing.

#### **Protein Digestion**

Following acetone precipitation, the precipitates were centrifuged for 5 min at 2000g. Acetone was discarded, and the resulting pellets were resuspended in 5 mL of denaturing buffer consisting of 6 M urea, 2 M thiourea, 10 mM HEPES, pH 8.0. Approximate protein concentration was determined using the Bradford assay (Bio-Rad, Hercules, CA, USA), and protein disulfides were reduced with dithiothreitol (DTT) at 1 mM final concentration for 60 min at room temperature (RT). Following DTT reduction, free cysteine thiols were alkylated with chloroacetamide (5 mM final) for 60 min at RT in the dark. Lys-C protease (Wako Chemicals, Richmond, VA, USA) at a ratio of 1:100 to the total protein amount was added and allowed to incubate at 30 °C for 4 h. Urea concentration was diluted to 2 M using 50 mM ammonium bicarbonate, and the samples were incubated overnight at 37 °C with trypsin (1:50 w/w) (Life Technologies, Carlsbad, CA, USA).

#### C<sub>18</sub> Sep-Pak Cleanup of Peptides

Following digestion, the resulting peptide mixtures were acidified with trifluoroacetic acid (TFA) to 2% final concentration and centrifuged at 4000g for 5 min, and supernatants were transferred to reversed-phase  $C_{18}$  Sep-Pak cartridges (Waters, Milford, MA, USA) for desalting and concentration. Sep-Pak cartridges were prepared by sequential washing with methanol, acetonitrile, and 0.1% TFA prior to loading of the peptide mixtures. Gravity was used for washing and loading of the samples. Sep-Pak cartridges were stored at 4 °C until further processing.

Peptides were eluted from Sep-Pak with 40% (4 mL) and 60% (2 mL) acetonitrile sequentially. For samples eluted for HpH fractionation, the elutes were dried in a SpeedVac centrifuge for 40 min at 45 °C, and peptide concentration was determined by Nanodrop (Thermo Fisher Scientific, Bremen, Germany) measurement at  $A_{280nm}$ .

#### Basic Reversed-Phase (HpH) High-Pressure Liquid Chromatography (HPLC) Fractionation

A few milligrams (2 to 3) of peptide mixture from biological replicates (each one resulting from a single 245 mm<sup>2</sup> cell culture plate) was fractionated using a Waters XBridge BEH130 C18 3.5  $\mu$ m 4.6 × 250 mm column on a Ultimate 3000 HPLC (Dionex, Sunnyvale, CA, USA) operating at 1 mL/min. A rheodyne MXII pump (IDEX Corporation, Rohnert Park, CA, USA) was coupled to the HPLC and used to inject sample into the column. For initial experiments, buffer A consisted of 10 mM ammonium formate and buffer B consisted of 10 mM ammonium formate with 90% acetonitrile; both buffers were adjusted to pH 10 with ammonium hydroxide as described previously.<sup>19</sup> For experiments conducted without ammonium formate, 10 mM ammonium hydroxide was used as the only additive to the mobile phases.

A similar injection protocol and gradient were used for all fractionation experiments; all fractions were collected using a Dionex AFC-3000 fraction collector in a 96 deep well plate at 1 min intervals. Samples were initially loaded onto the column at 1 mL/min for 4 min, after which the fractionation gradient

## Scheme 1. Overview of the Workflows Presented in This Study<sup>a</sup>



"Tryptic peptide mixtures are first fractionated using either a strong cation exchange or high-pH reversed-phase approach followed by titanium dioxide phosphopeptide enrichment. This is followed by a cleanup and loading step prior to LC-MS analysis.

commenced as follows: 1% B to 25% B in 50 min, 60% B in 4 min, and ramped to 70% B in 2 min. At this point, fraction collection was halted, and the gradient was held at 70% B for 5 min before being ramped back to 1% B, where the column was then washed and equilibrated.

The total number of fractions concatenated was set to 14 (Scheme 1) throughout all experiments. For the optimized method, the initial fractions were pooled and represented as 1 fraction and concatenated with other fractions as described.<sup>17</sup> Prior to concatenation, ammonium hydroxide and/or ammonium formate were evaporated in a SpeedVac operating at 60 °C. It should be noted that lower temperatures are preferable when analyzing labile modifications such as O-glycosylation.

#### Strong Cation Exchange (SCX) Fractionation

SCX fractionation was performed as described.<sup>20</sup> Briefly, 2 to 3 mg of peptides was fractionated on a 1 mL Resource S column (GE Healthcare, Sweden) using an ÄKTA FPLC system (GE Healthcare, Sweden). Peptides eluted from Sep-Pak were

directly injected onto the column. Peptides were separated by increasing salt concentration at 1 mL/min from 100% SCX buffer A (5 mM  $KH_2PO_4$ , pH 2.7, 30% ACN) to 30% SCX buffer B (5 mM  $KH_2PO_4$ , pH 2.7, 350 mM KCl, 30% ACN) over the course of 30 min; B was then increased to 100%, where it was held for 6 min. Fractions were collected at 2 min intervals (2 mL each) and pooled at various intervals to bring total fraction number to 11 (Scheme 1).

#### **Phosphopeptide Enrichment**

For all experiments, phosphopeptides from each HpH and SCX fraction were enriched in batch mode with metal oxide affinity enrichment (MOAC) using titanium dioxide beads<sup>21,22</sup> (5  $\mu$ m Titansphere, GL Sciences, Japan). TiO<sub>2</sub> beads were preincubated in 2,5-dihydroxybenzoic acid (20 mg/mL) in 80% ACN and 1% TFA (5  $\mu$ L/mg of beads) for 20 min. Prior to addition of the beads, all fractions were brought to 80% acetonitrile and 5% TFA in a final volume of 10 mL. Two milligrams (in 10  $\mu$ L of DHB solution) of beads was added to each fraction, which

Table 1. High-pH Reversed-Phase (HpH) and Strong Cation Exchange (SCX) Phosphopeptide Variants Comparison Based on Four Biological Replicates for Each

fractionation	1 P	2 P	≥3 P	total phospho	non-phospho	% enrichment
HpH	12 609 (±2655)	4199 (±1005)	759 (±165)	17 566 (±3737)	892 (±256)	95 (±2)
SCX	1561 (±330)	3360 (±1077)	1295 (±519)	6215 (±1759)	350 (±287)	94 (±6)

was then incubated for 30 min while rotating. After incubation, fractions were centrifuged at 4000g for 5 min, and supernatant was removed.

Beads were washed with 30% ACN and 1% TFA and loaded onto C<sub>8</sub> STAGE-tip (3 M Empore, St. Paul, MN, USA) and centrifuged at 500g. Beads were washed on-tip with 50% ACN and 1% TFA followed by 80% ACN and 1% TFA, after which the phosphorylated peptides were eluted first with 20  $\mu$ L of 5% NH<sub>4</sub>OH followed by 20  $\mu$ L of 10% NH<sub>4</sub>OH with 25% ACN. Eluted peptides were concentrated in a SpeedVac, loaded onto C<sub>18</sub> STAGE-tips,<sup>23</sup> and primed for LC–MS analysis.

### LC-MS/MS Analysis

All phosphopeptide samples were analyzed with Easy-nLC 1000 (Proxeon, Odense, Denmark) coupled to Thermo Fisher Q-Exactive Orbitrap or Q-Exactive Orbitrap Plus. Peptides were separated on in-house packed column (75  $\mu$ m i.d. × 15 cm length) with 1.9  $\mu$ m C<sub>18</sub> beads (Dr. Maisch, Germany). Separation was achieved using a linear gradient of increasing buffer B (80% ACN and 0.1% formic acid) and decreasing buffer a (0.1% formic acid) at 250 nL/min. Buffer B was increased to 30% B in 70 min and ramped to 40% B in 5 min followed by a quick ramp to 80% B, where it was held for 5 min before a quick ramp back to 5% B, where it was held and the column was re-equilibrated.

Q-Exactive mass spectrometer was operated in positive polarity mode with capillary temperature of 275 °C. Full MS survey scan resolution was set to 70 000 with an automatic gain control (AGC) target value of  $1 \times 10^6$  for a scan range of  $350-1750 \ m/z$ . A data-dependent top 10 method was operated during which higher-energy collisional dissociation (HCD)<sup>24</sup> spectra were obtained at 17 500 MS<sup>2</sup> resolution with AGC target of  $1 \times 10^5$  and maximum ion injection time (IT) of 48 ms,  $4 \ m/z$  isolation width, and normalized collisional energy (NCE) of 25. Former precursor ions targeted for HCD were dynamically excluded of 15 s. Q-Exactive Plus was operated with similar parameters with the exception of 35 000 MS<sup>2</sup> HCD resolution, 108 ms maximum injection time (IT), and narrow isolation window of 1.3 m/z.

#### **Data Analysis**

All files were analyzed using the MaxQuant software suite 1.4.1.4 (www.maxquant.org) with the Andromeda search engine.<sup>25</sup> For NIH-3T3 cell line sample files, the HCD MS/ MS spectra were searched against an in silico tryptic digest of Mus musculus proteins from the UniProt sequence database (v. April 2014) containing 81 824 sequences, including spliced isoforms, that is split between 24 488 reviewed protein entries (Swiss-Prot IDs) and 57 336 unreviewed protein entries (TrEMBL IDs). All MS/MS spectra were searched with the following MaxQuant parameters for phosphopeptide identification: acetyl (protein N-terminus), methionine oxidation, phosphorylation (STY), and glutamine cyclization to pyroglutamate were searched as variable modifications; cysteine carbamidomethylation was set as fixed modification; max 3 missed cleavages; and precursors were initially matched to 4.5 ppm tolerance and 20 ppm for fragment spectra. Peptide

spectrum matches, proteins, and sites were automatically filtered to a 1% false discovery rate based on Andromeda score, peptide length, and individual peptide mass errors. Modified peptides required a minimum peptide length of at least seven amino acids (AA) and a minimum Andromeda score of 40 to be considered a positive hit. Analysis of phosphopeptide variants was performed using the MaxQuant Evidence " table. Confidently assigned phosphorylation sites with localization probabilities greater than 75% were defined as Class I sites and were used as site localization cutoff from the Phospho (STY)Sites table generated by MaxQuant analysis, and the Evidence table was used for phosphopeptide variant analysis. All raw files from this study have been deposited to the ProteomeXchange Consortium<sup>26</sup> with data set identifier PXD001404 via the PRIDE partner repository.

Functional analysis for gene ontology (GO) enrichment was performed using DAVID.<sup>27,28</sup> Corresponding UniProt identifiers to proteins of Class I sites for each experiment were uploaded as a gene list. Background based on an LC–MS experiment of the NIH-3T3 proteome run was utilized. A cutoff of p < 0.05 was utilized for all GO categories in our analysis. Sequence analysis of phosphorylation sites was performed using iceLogo 1.2.<sup>29</sup> Peptide sequences were uploaded as positive and negative set, and the percent difference was selected as the scoring system, with p values less than 0.01.

#### RESULTS AND DISCUSSION

#### Comparison of High-pH Reversed-Phase (HpH) and Strong Cation Exchange (SCX) for Phosphoproteomics

To determine the efficacy of basic reversed-phase (HpH) fractionation for large-scale phosphoproteomics, we analyzed tryptic digests of whole-cell lysates from mouse NIH-3T3 cells that were separated by HpH followed by TiO<sub>2</sub> enrichment of phosphopeptides from concatenated fractions. The resulting phosphopeptide fractions were separated on-line by nanoflow liquid chromatography and analyzed by high-resolution tandem mass spectrometry on a Q-Exactive instrument. We carefully evaluated the number of the identified phosphopeptides and their properties, and, on the basis of this, we optimized the HpH fractionation and concatenation strategy. For comparative purposes, strong cation exchange (SCX) provided a good reference point, as it has become a widely established protocol for fractionation of peptides and phosphopeptides (Scheme 1). In all experiments, we fractionated total digests first and enriched phosphopeptides afterward. We reasoned that the decreased complexity of the sample mixtures in fractions would allow for greater enrichment efficiency of phosphopeptides. This was confirmed in the comparison of HpH and SCX fractionation, where we observed phosphopeptide enrichment efficiencies of more than 90% and up to 97% in some experiments (Table 1 and Supporting Information Table 1). For both HpH and SCX, we maintained a total of 14 fractions. In the HpH chromatography, we collected a total of 56 fractions that were pooled and concatenated to 14 (Figure 1), and for the optimized SCX protocol, we collected 11 fractions,

#### Journal of Proteome Research



**Figure 1.** (A) Eleven total SCX fractions were collected before  $\text{TiO}_2$  enrichment of phosphopeptides. Following enrichment, a second round of TiO<sub>2</sub> enrichment was performed on the fractions from the initial flow through fractions, where a large number of phosphopeptides are expected to elute. (B) Following concatenation to a total of 14 or 11 fractions, TiO<sub>2</sub> enrichment was performed on each fraction individually. HpH double TiO<sub>2</sub>: In the case with 11 fractions, supernatants from initial enrichments were pooled into three additional fractions, and incubation with TiO<sub>2</sub> was performed again, generating a total of 14 fractions.

from which double  $TiO_2$  (MOAC) enrichment was performed on 3 fractions for a total of 14 (Figure 1). All SCX and HpH fractions were analyzed using the same 70 min LC gradient and the same MS settings (see Experimental Procedures).

The number of phosphopeptides from HpH was generally higher across fractions compared to that from SCX, where we observed that a few fractions carried the main proportion of phosphopeptides (Supporting Information Figure 1). Using four biological replicates from each experiment, we found that HpH had an exceptional ability to separate singly phosphorylated peptides, as we found an average of 12 609 ( $\pm$ 2655) singly phosphorylated peptides in the HpH-separated samples compared to 1561 ( $\pm$ 330) when using SCX, a difference of almost 8-fold (Table 1 and Supporting Information Table 1). HpH fractionation also revealed a slight advantage for the enrichment of doubly phosphorylated peptides, as we found an average of 4199 (±1005) compared to 3360 (±1077) in the SCX experiments. However, SCX displayed a higher propensity toward peptides with three or more phosphoryl groups due to its advantage of separation based on charge (Table 1 and Supporting Information Table 1). The analysis of localized class I phosphorylation sites (pSTY) showed a total of 15 557 phosphorylation sites enriched after the HpH fractionations and only 6827 from SCX. This indicates that separating peptides with SCX produced less than half of the number of class I sites compared to that from HpH fractionation. Excellent overlap of these sites was observed, as 86% of the class I sites identified from SCX experiments were also identified in HpH (Figure 2A and Supporting Information Table 2), demonstrating that HpH is indeed superior for in-depth phosphoproteomics. Altogether, these results indicate a severe undersampling of singly phosphorylated peptides with SCX fractionation, suggesting that the greater resolving power via hydrophobic interactions of HpH is required for efficient separation and detection of phosphopeptides.

Technical Note

#### **Optimization of HpH for Phosphoproteomics**

As described previously,<sup>18</sup> at higher pH values, multiphosphorylated peptides attain a high number of negative charges, thus reducing interactions with the reversed-phase material and leading to the loss of a high percentage of multiphosphorylated peptides in the initial flow through. We observed a similar trend with our off-line fractionation setup (Supporting Information Figure 1). To maximize the total number of phosphopeptides identified and to increase the amount of multiphosphorylated peptides identified with HpH, we made a few informed changes to our strategy (HpH Opt). We increased the quality of the HCD fragment spectra and performed double incubation of specific HpH fractions or pools of fractions (Figure 1B). With optimized parameters, we were able to increase the total number phosphopeptide variants to almost 40 000, an increase of more than 2-fold compared to that from the initial HpH strategy and 6-fold to that from the SCX experiments (Tables 1 and 2). Furthermore, we were able to dramatically increase the number of class I phosphorylation sites by almost 4-fold compared to that from SCX and 2-fold compared to that from previous HpH experiments (Figure 2B,C).

Combination of optimized MS parameters with double TiO<sub>2</sub> incubation (HpH Opt  $TiO_2$ ) resulted in identification of 32 446 phosphopeptides, an increase of 84% from the average of previous HpH experiments (Table 2). Additionally, class I sites increased by 66% to 18 250 from one experiment over the average number of sites from initial HpH experiments (Supporting Information Table 2). Using this double TiO<sub>2</sub> enrichment strategy, we were able to significantly increase the number of phosphopeptides with three or more phosphoryl groups to more than 2000 (Figure 2D). This number of multiphosphorylated peptides was also substantially higher compared to the average of the SCX experiments. These results demonstrate that high coverage of multiphosphorylated peptides is possible with HpH and illustrates the capacity of HpH to considerably increase the depth of the phosphoproteome.

In phosphoproteomics, we are faced with the challenge of localizing phospho groups in the identified peptide sequence

6180

#### Journal of Proteome Research

Technical Note



**Figure 2.** (A) Analysis of overlap of class I phosphorylation sites between SCX and HpH experiments. (B) Class I site overlap between HpH (n = 4) and HpH Opt (n = 3) experiments performed on Q-Exactive Plus with optimized parameters. (C) Number of class I sites arising from the three different strategies. (D) Number of multiphosphorylated peptides identified by SCX, HpH, and HpH Opt with double TiO<sub>2</sub> incubation.

fractionation	biological replicate	1 P	2 P	≥3 P	total phospho	non-phospho	% enrichment
HpH Opt	1	31 082	7411	820	39 283	4833	89.05
	2	30 344	5962	767	37 073	4765	88.61
HpH Opt Double ${\rm TiO}_2$	1	20 785	9198	2462	32 445	3197	91.03

with single amino acid accuracy. To successfully achieve this, high sequence coverage in peptide fragmentation spectra is a necessity. Higher quality HCD spectra allow for better y and b ion series coverage of the peptide, including accurate localization of the phosphoryl group. In the case of Orbitrap instruments, as presented in this study, higher scanning time is required for higher quality spectra, doubling the resolution results with a doubling of the total scan time. Consequently, the percentage of peptides identified increases at the cost of scan speed. As described by Kelstrup et al.,<sup>30</sup> optimization of parameters for sensitive and fast analysis depends on a variety of factors such as sample complexity, starting material, and run time. For samples of high complexity and high sample amounts, fast scanning methods are preferred in order to sequence as many peptides as possible for high coverage of the proteome.<sup>30,31</sup> For samples that are less complex (i.e., of low abundance, such as fractionated and enriched), scan speed is not a limiting factor due to low number of co-eluting peptides.

In this case, sensitive scanning methods are optimal for identification and localization of phospho groups (Figure 3A). Despite the high number of phosphopeptides identified in each fraction in the first four HpH experiments, the percentage of MS/MS identified (peptide spectrum matches post FDR filtering at 1%) was only on the order of 6% on average (Supporting Information Table 3). This indicated that the general quality of the acquired HCD spectra was too low. We reasoned that increasing the HCD spectrum quality by doubling the Orbitrap analyzer resolution from 17 500 to 30 000 (at fwhm) and by utilizing sub 2 m/z precursor isolation windows (1.3 m/z) with higher c-trap injection times (108 ms)would increase identification rates (Figure 3A). Most importantly, with higher injection times (IT), peptide ions are accumulated for a longer period, thus increasing the MS signal intensities of the fragment ions. Additionally, narrow isolation would reduce the amount of co-fragmenting interfering species, thus reducing the fragment spectra



Technical Note



Figure 3. (A) Diagram demonstrating optimal range for MS parameters depending on phosphoproteomics sample complexity. The colored boxes represent the ideal working area. (B) Box plot of Andromeda score distribution for phosphopeptides detected in the three different experiments.



Figure 4. (A) Number of phosphopeptides detected over time when performing high-pH reversed-phase experiments on the same column. (B) Unique phosphopeptide variants analyzed from biological replicates of experiments performed with (HpH) and without (HpH Opt) ammonium formate in the running buffers. Unique phosphopeptide variants are accumulated over fractions. The various symbols represent replicate experiments.

complexity, which can hinder identification and localization. The strategy was validated, as the average percentage of MS/ MS identified from HpH optimized experiments was 21.6%, an increase of almost 4-fold compared to that with the previous MS acquisition method (Supporting Information Table 3). Besides the higher number of phosphopeptide variants and class I sites detected (Table 2 and Supporting Information Table 2), we observed that the Andromeda scores for phosphopeptides were significantly higher using the optimized parameters (Figure 3B). The average Andromeda score of 142.8 (more than 60% increase) indicated that sequence assignment can be achieved with higher confidence. Higher

scores for optimized parameters were independent of the fractionation method, as SCX and HpH had similar average Andromeda scores, 85.7 and 88.8, respectively, despite higher number of phosphopeptides sequenced using HpH. These results demonstrate the importance of having high-quality fragment spectra for analysis of fractionated phosphopeptides.

Although these results validated our initial assessment and optimization of the HpH protocol, further experiments over time showed a sharp decline in each measurable category (i.e., the number of phosphopeptides identified) (Figure 4A). As a note, the original HpH and HpH Opt  $TiO_2$  experiments were performed on the same fractionation column before degrada-



Technical Note



Figure 5. (A) IceLogo sequence motif analysis of phosphorylation sites. Phosphorylation sites in peptides with missed cleavages are compared to phosphorylation sites in peptides without missed cleavages. Residues  $\pm 15$  from the phosphorylation site are mapped to determine the percent difference at a *p* value of less than 0.001. (B) Overrepresentation of phosphorylated amino acids in missed cleaved phosphopeptides compared to phosphorylation sites in peptides without missed cleavages. Bars are represented as  $\log_{10}$ -transformed *p* values based on Fisher's exact test.

tion was observed. After careful evaluation of the entire protocol (enrichment, fractionation, MS instrument, etc.), we concluded that the decline in performance was due to severe degradation in the separation power of the HpH  $C_{18}$  column. As mentioned by Percy et al.,<sup>32</sup> removal of ammonium formate from running buffers can increase column robustness and performance when performing peptide separations at high pH. Using a new, although identical, column, we investigated the performance of high-pH fractionation for phosphopeptide analysis with only ammonium hydroxide in the mobile phases (HpH Opt experiments) and observed no detrimental effects in the separation efficiency and coverage of phosphorylation sites (Table 2). In fact, we observed a significant increase in the total number of phosphopeptides detected using this simple buffer system. These surprising results led us to further assess the impact of ammonium formate in the running buffers. Analysis of unique phosphopeptide variants displayed a linear increase in the number of total phosphopeptides over the fractions, indicating a small fraction-to-fraction variation (Figure 4B). These results demonstrate that a similar separation of phosphopeptides is achieved without the addition of ammonium formate at higher pH. Although the column manufacturer reports stability at high pH and high column temperatures, compatibility with buffer systems for separation of peptides is equally important. Therefore, we recommend future high-pH reversed-phase experiments to be performed in the absence of ammonium formate and instead to use only a simple buffer system that consists of a low concentration of ammonium hydroxide at ambient column temperature followed by thorough column washing with neutral buffers (water and acetonitrile) after each injection and separation. Ultimately, characterization of the HpH method demonstrated a substantial improvements from standard fractionation methods, and the possibility of applying it to other classes of peptides makes this a very appealing technique.<sup>33</sup> Together with the optimized MS parameters, close to 40 000 phosphopeptide variants can be detected, and comprehensive coverage of the phosphoproteome is now possible in less than 24 h of total measurement time.

#### **Analysis of Phosphopeptides Properties**

The large phosphopeptide data set arising from stimulated growing cells in culture allowed us to study the physicochemical properties of phosphopeptides in detail. Phosphopeptides, unlike unmodified tryptic peptides, tend to exhibit different MS/MS characteristics; thus, greater understanding of their intrinsic chemical and physical properties can facilitate efficient analysis of phosphoproteomes. The presence of the phosphoryl group has an effect on trypsin digestion of proteins<sup>34</sup> and can alter the charge distribution of peptides in the gas phase (as well as in solution). One specific feature we observed was that a large percentage of phosphopeptides had a charge state of three or more, which is higher than that of typical unmodified tryptic peptides (Supporting Information Figure 2). As a result, the m/z distribution was expected to be lower than that of unmodified peptides; however, the opposite was observed (Supporting Information Figure 3), where the mean of the m/z distribution of phosphopeptides was roughly 80 m/z units higher (727.59) m/z vs 646.95 m/z). We reasoned that this could be attributed to generally longer peptide lengths of phosphopeptides and to the presence of the phosphoryl groups (+79.96 Da). Analyses of peptide length showed that the phosphopeptides were, on average, five amino acid residues longer, with an average length of 17 for those without any missed cleavage sites (Supporting Information Table 4). Further analysis revealed that more than half of the unique phosphopeptide sequences (56%) carried missed cleavages, compared to less than one-fourth for unmodified peptides (23%). Sequence motif analysis using iceLogo of phosphopeptides carrying missed cleavages (positive set) showed a significant enrichment of Arg/Lys residues in -1,

-2, and -3 positions N-terminal to the phosphorylation site (Figure 5). Surprisingly, we observed a significant enrichment of tyrosine phosphorylation sites ( $p < 10 \times 10^{-9}$ ) from phosphopeptides without missed cleavages compared to that from missed cleaved phosphopeptides (Figure 5B), suggesting that tyrosine phosphorylation may not form similar salt bridges with proximal arginine and lysine residues,<sup>35</sup> which can prevent efficient trypsin cleavage. These results were consistent with earlier findings, whereby using synthetic peptides it was reported that phosphorylated tyrosines proximal to arginine or lysine residues were much more amiable to tryptic digestion compared to those peptides carrying phosphoserine or -threonine.<sup>34</sup> Phosphotyrosines are particularly interesting because tyrosine kinases are key initiators of signaling cascades.<sup>36</sup>

# Phosphoproteome Coverage by HpH and Its Impact on Cell Signaling Analyses

Although serine and threonine generally make up most of the phosphorylation sites detected in phosphoproteomics work-flows (~98% in our studies) (Supporting Information Figure 4), tyrosine phosphorylation is a key component of signal transduction and cellular responses.<sup>37</sup> To overcome the low abundance of tyrosine phosphorylation, phosphotyrosine-specific antibodies are typically utilized for enrichment and immunoprecipitation of tyrosine phosphorylated peptides.<sup>36</sup> In our HpH experiments of the NIH-3T3 phosphoproteome, we observed a very large coverage and overrepresentation of phosphotyrosine class I sites when compared with that from SCX (Table 3 and Supporting Information Figure 4). We

 Table 3. Number of Class I Phosphotyrosine Sites Covered

 with the Different Fractionation Strategies

fractionation	biological replicate	class I pY	unique experiment	unique fractionation	total
НрН	1	148	196	520	526
	2	87			
	3	75			
	4	71			
HpH Opt	1	322	496		
	2	328			
HpH Opt Double TiO <sub>2</sub>	1	205			
SCX	1	26	39	39	
	2	16			
	3	14			
	4	22			

found that the majority (72%) of phosphotyrosine containing peptides were singly phosphorylated and 22% were doublephosphorylated (data not shown). The ability of HpH fractionation to resolve eight times as many singly phosphorylated peptides compared to that of SCX indicates a correlation with the increased coverage of phosphotyrosine peptides. Close to 500 localized tyrosine phosphorylation sites were observed in the optimized HpH experiments (Table 3), representing 357 phosphoproteins. Gene ontology (GO) analysis revealed enrichment of transmembrane receptor protein tyrosine kinase signaling pathways such as ErbB, VEGF, and other growth factor signaling pathways and other biological processes linked to signaling cascades (data not shown). Cell compartment (CC) analysis of the tyrosine phosphorylated proteins showed enrichment for plasma membrane proteins, suggesting that HpH fractionation permits coverage of membrane tyrosine phosphorylation without affinity enrichment. It should be noted that phosphotyrosine coverage is expected to be even greater under specific conditions such as short growth factor stimulation, which specifically stimulates receptor tyrosine kinases. Nevertheless, our results obtained with a 10 min stimulation of growing cells with serum demonstrates the power of HpH for in-depth analysis of the tyrosine phosphoproteome.

To explore the extent and coverage of cell signaling pathways covered by off-line HpH compared to that with SCX fractionation in large-scale phosphoproteome experiments, we performed gene ontology (GO) enrichment analysis using DAVID of the SCX and HpH data sets. As expected, we observed a greater number of enriched categories of biological processes, compartmental categorization and molecular function (data not shown) above the cutoff (p < 0.05), and higher number of counts per category in experiments conducted with HpH compared to that with SCX. Surprisingly, some categories were underrepresented in the SCX experiments but overrepresented in HpH experiments. For instance, analysis of compartmental categorization revealed overrepresentation of cytosolic phosphoproteins in HpH experiments but not in SCX (Chart 1). We believe that the increased coverage is a result of large number of singly phosphorylated peptides derived from proteins in the cytosol identified by HpH fractionation. Understanding the role of phosphorylation in different cellular organelles requires deep coverage of the phosphoproteome, and our data sets demonstrate that this is now possible with HpH fractionation. We imagine that HpH fractionation in combination with quantitative proteomics technologies such as stable isotope labeling by amino acids in cell culture (SILAC)<sup>38</sup> will be particularly useful for analyzing global and dynamic phosphorylation site changes in cell signaling pathways.

#### CONCLUSIONS

Reduction of the high dynamic range of protein abundance is crucial for deep coverage of the proteome and especially the phosphoproteome, where the dynamic range is even more pronounced.<sup>1</sup> This issue is usually addressed in two ways: either through introduction of more powerful and sensitive mass spectrometric instrumentation or by decreasing sample complexity via fractionation. Although great advances in instrument sensitivity and sequencing speed have been made, fractionation is still required for in-depth coverage of phosphoproteomes. Off-line high-pH reversed-phase fractionation is exceptional in its resolving power for the separation of peptides and is highly orthogonal to low-pH reversed-phase separation used in tandem with MS analysis. Deep coverage can be crucial when attempting to understand complex biological systems. As our results indicate, greater coverage has implications in cell signaling analyses. Robust and reproducible sample preparation and MS methods are essential, as global phosphoproteomics is the method of choice for unbiased analysis of cell signaling networks and is becoming routine in many non-MS expert laboratories.

Our results show that phosphopeptide separation based on high-pH reversed-phase chromatography is a powerful fractionation method for global phosphoproteomics and that it is superior to traditional SCX-based strategies. Removal of ammonium formate from high-pH buffers can increase column performance over time, and double TiO<sub>2</sub> enrichment allows for high coverage of multiphosphorylated peptides from pooled Chart 1. Results from GO Enrichment and Analysis Using DAVID Presented on Selected Categories for Each of the Three Experiments<sup>a</sup>



 $p^{a}$  values for each category are  $-\log_{10}$ -transformed and plotted. The number of counts for each significantly enriched category from the corresponding experiments are indicated.

HpH fractions. Similarly, our results indicate that MS parameters must be optimized based on the samples analyzed to increase the general quality of the HCD spectra, contributing to greater phosphorylation site localization. We hope that this study will serve as a useful resource and stimulate the wide adoption of high-pH-based fractionation in phosphoproteomics studies.

#### ASSOCIATED CONTENT

#### **S** Supporting Information

Table 1: Phosphopeptide variants for each individual biological replicate arising from HpH and SCX. Table 2: Class I phosphorylation sites for each biological replicate of SCX, HpH, and HpH Opt. Table 3: (A) Percent of HCD spectra (MS/MS) identified and MS/MS spectra identified (SIL) for which an isotope pattern was detected in each replicate. (B) Average identified MS/MS spectra for each individual experiment. Table 4: (A) Number of unmodified peptides with and without missed tryptic cleavage sites from a typical large-scale proteomics data set. (B) Number of phosphopeptides with and without missed tryptic cleavages. The average peptide sequence lengths (number of amino acid residues) are also indicated. Figure 1: Unique phosphopeptide variants are plotted based on total counts (Å) and with varying number of phosphoryl groups (B-D). For comparison purposes, three biological replicates performed together in series were used. Figure 2: Peptide charge state as percentages for unmodified and phosphopeptides. Figure 3: Peptide precursor m/z ratios in bins of 50 units are plotted for unmodified and phosphophorylated peptides. Figure 4: Phosphorylation site distributions of serine, threonine, and tyrosine based on all class I sites from this study. Excel workbooks for phosphopeptide variants for each experiment and phosphorylation sites. This material is available free of charge via the Internet at http://pubs.acs.org.

#### AUTHOR INFORMATION

#### **Corresponding Author**

\*E-mail: jesper.olsen@cpr.ku.dk. Tel.: +45 35 32 50 00. Fax: +45 35 32 50 01.

#### Notes

The authors declare no competing financial interest.

#### ACKNOWLEDGMENTS

The Novo Nordisk Foundation (NNF) Center for Protein Research is supported by an NNF donation. The work was supported by the Seventh Framework Program of the European Union (262067-PRIME-XS). The authors thank Mats Wikström for HPLC assistance as well as Christian Kelstrup and Rosa Rakownikow Jersie-Christensen for helpful discussions. The authors additionally thank Dorte Breinholdt Bekker-Jensen for assistance with figures and helpful discussions.

#### REFERENCES

(1) Olsen, J. V.; Mann, M. Status of large-scale analysis of post-translational modifications by mass spectrometry. *Mol. Cell. Proteomics* **2013**, *12*, 3444–3452.

(2) Lemmon, M. A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. *Cell* **2010**, *141*, 1117–1134.

(3) de Graaf, E. L.; Giansanti, P.; Altelaar, A. F. M.; Heck, A. J. R. Single step enrichment by Ti<sup>4+</sup>-IMAC and label free quantitation enables in-depth monitoring of phosphorylation dynamics with high reproducibility and temporal resolution. *Mol. Cell. Proteomics* **2014**, *13*, 2426–2434.

(4) Lundby, A.; Andersen, M. N.; Steffensen, A. B.; Horn, H.; Kelstrup, C. D.; Francavilla, C.; Jensen, L. J.; Schmitt, N.; Thomsen, M. B.; Olsen, J. V. In vivo phosphoproteomics analysis reveals the cardiac targets of  $\beta$ -adrenergic receptor signaling. *Sci. Signaling* **2013**, *6*, rs11.

(5) Washburn, M. P.; Wolters, D.; Yates, J. R. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. *Nat. Biotechnol.* **2001**, *19*, 242–247.

(6) Villen, J.; Gygi, S. P. The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry. *Nat. Protoc.* **2008**, *3*, 1630–1638.

(7) Di Palma, S.; Boersema, P. J.; Heck, A. J. R.; Mohammed, S. Zwitterionic hydrophilic interaction liquid chromatography (ZIC-HILIC and ZIC-cHILIC) provide high resolution separation and increase sensitivity in proteome analysis. *Anal. Chem.* **2011**, *83*, 3440–3447.

(8) Hao, P.; Guo, T.; Li, X.; Adav, S. S.; Yang, J.; Wei, M.; Sze, S. K. Novel application of electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) in shotgun proteomics: comprehensive profiling of rat kidney proteome. *J. Proteome Res.* **2010**, *9*, 3520–3526.

(9) Beausoleil, S. A.; Jedrychowski, M.; Schwartz, D.; Elias, J. E.; Villén, J.; Li, J.; Cohn, M. A.; Cantley, L. C.; Gygi, S. P. Large-scale characterization of HeLa cell nuclear phosphoproteins. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 12130–12135.

(10) D'Souza, R. C. J.; Knittle, A. M.; Nagaraj, N.; Dinther, M. v.; Choudhary, C.; Dijke, P. t.; Mann, M.; Sharma, K. Time-resolved dissection of early phosphoproteome and ensuing proteome changes in response to TGF- $\beta$ . Sci. Signaling **2014**, 7, rs5.

(11) Gruhler, A.; Olsen, J. V.; Mohammed, S.; Mortensen, P.; Faergeman, N. J.; Mann, M.; Jensen, O. N. Quantitative phosphoproteomics applied to the yeast pheromone signaling pathway. *Mol. Cell. Proteomics* **2005**, *4*, 310–327.

(12) Huttlin, E. L.; Jedrychowski, M. P.; Elias, J. E.; Goswami, T.; Rad, R.; Beausoleil, S. A.; Villén, J.; Haas, W.; Sowa, M. E.; Gygi, S. P. A tissue-specific atlas of mouse protein phosphorylation and expression. *Cell* **2010**, *143*, 1174–1189.

(13) Olsen, J. V.; Blagoev, B.; Gnad, F.; Macek, B.; Kumar, C.; Mortensen, P.; Mann, M. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. *Cell* **2006**, *127*, 635–648.

(14) Pinkse, M. W. H.; Mohammed, S.; Gouw, J. W.; van Breukelen, B.; Vos, H. R.; Heck, A. J. R. Highly robust, automated, and sensitive online TiO<sub>2</sub>-based phosphoproteomics applied to study endogenous phosphorylation in *Drosophila melanogaster*. J. Proteome Res. **2008**, *7*, 687–697.

(15) McNulty, D. E.; Annan, R. S. Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. *Mol. Cell. Proteomics* **2008**, *7*, 971–980.

(16) Gilar, M.; Olivova, P.; Daly, A. E.; Gebler, J. C. Orthogonality of separation in two-dimensional liquid chromatography. *Anal. Chem.* **2005**, 77, 6426–6434.

(17) Wang, Y.; Yang, F.; Gritsenko, M. A.; Wang, Y.; Clauss, T.; Liu, T.; Shen, Y.; Monroe, M. E.; Lopez-Ferrer, D.; Reno, T.; Moore, R. J.; Klemke, R. L.; Camp, D. G., II; Smith, R. D. Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells. *Proteomics* **2011**, *11*, 2019–2026.

(18) Ficarro, S. B.; Zhang, Y.; Carrasco-Alfonso, M. J.; Garg, B.; Adelmant, G.; Webber, J. T.; Luckey, C. J.; Marto, J. A. Online nanoflow multidimensional fractionation for high efficiency phosphopeptide analysis. *Mol. Cell. Proteomics* **2011**, 10.

(19) Udeshi, N. D.; Svinkina, T.; Mertins, P.; Kuhn, E.; Mani, D. R.; Qiao, J. W.; Carr, S. A. Refined preparation and use of anti-diglycine remnant (K-*e*-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. *Mol. Cell. Proteomics* **2012**, *12*, 825–831.

(20) Francavilla, C.; Hekmat, O.; Blagoev, B.; Olsen, J. V. SILACbased temporal phosphoproteomics. *Methods Mol. Biol.* 2014, *1188*, 125–148.

(21) Larsen, M. R.; Thingholm, T. E.; Jensen, O. N.; Roepstorff, P.; Jørgensen, T. J. D. Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. *Mol. Cell. Proteomics* **2005**, *4*, 873–886.

(22) Pinkse, M. W. H.; Uitto, P. M.; Hilhorst, M. J.; Ooms, B.; Heck, A. J. R. Selective isolation at the femtomole level of phosphopeptides from proteolytic digests using 2D-NanoLC–ESI–MS/MS and titanium oxide precolumns. *Anal. Chem.* **2004**, *76*, 3935–3943.

(23) Rappsilber, J.; Mann, M.; Ishihama, Y. Protocol for micropurification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. *Nat. Protoc.* **2007**, *2*, 1896–1906.

(24) Olsen, J. V.; Macek, B.; Lange, O.; Makarov, A.; Horning, S.; Mann, M. Higher-energy C-trap dissociation for peptide modification analysis. *Nat. Methods* **2007**, *4*, 709–712. (25) Cox, J.; Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* **2008**, *26*, 1367–1372.

(26) Vizcaíno, J. A.; Deutsch, E. W.; Wang, R.; Csordas, A.; Reisinger, F.; Ríos, D.; Dianes, J. A.; Sun, Z.; Farrah, T.; Bandeira, N.; Binz, P.-A.; Xenarios, I.; Eisenacher, M.; Mayer, G.; Gatto, L.; Campos, A.; Chalkley, R. J.; Kraus, H.-J.; Albar, J. P.; Martinez-Bartolomé, S.; Apweiler, R.; Omenn, G. S.; Martens, L.; Jones, A. R.; Hermjakob, H. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. *Nat. Biotechnol.* **2014**, *32*, 223–226.

(27) Huang, D. W.; Sherman, B. T.; Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.* **2009**, *37*, 1-13.

(28) Huang, D. W.; Sherman, B. T.; Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **2009**, *4*, 44–57.

(29) Colaert, N.; Helsens, K.; Martens, L.; Vandekerckhove, J.; Gevaert, K. Improved visualization of protein consensus sequences by iceLogo. *Nat. Methods* **2009**, *6*, 786–787.

(30) Kelstrup, C. D.; Young, C.; Lavallee, R.; Nielsen, M. L.; Olsen, J. V. Optimized fast and sensitive acquisition methods for shotgun proteomics on a quadrupole Orbitrap mass spectrometer. *J. Proteome Res.* **2012**, *11*, 3487–3497.

(31) Hebert, A. S.; Richards, A. L.; Bailey, D. J.; Ulbrich, A.; Coughlin, E. E.; Westphall, M. S.; Coon, J. J. The one hour yeast proteome. *Mol. Cell. Proteomics* **2014**, *13*, 339–347.

(32) Percy, A. J.; Simon, R.; Chambers, A. G.; Borchers, C. H. Enhanced sensitivity and multiplexing with 2D LC/MRM-MS and labeled standards for deeper and more comprehensive protein quantitation. *J. Proteomics* **2014**, *106*, 113–124.

(33) Mertins, P.; Qiao, J. W.; Patel, J.; Udeshi, N. D.; Clauser, K. R.; Mani, D. R.; Burgess, M. W.; Gillette, M. A.; Jaffe, J. D.; Carr, S. A. Integrated proteomic analysis of post-translational modifications by serial enrichment. *Nat. Methods* **2013**, *10*, 634–637.

(34) Dickhut, C.; Feldmann, I.; Lambert, J.; Zahedi, R. P. Impact of digestion conditions on phosphoproteomics. *J. Proteome Res.* **2014**, *13*, 2761–2770.

(35) Errington, N.; Doig, A. J. A phosphoserine–lysine salt bridge within an  $\alpha$ -helical peptide, the strongest  $\alpha$ -helix side-chain interaction measured to date. *Biochemistry* **2005**, *44*, 7553–7558.

(36) Francavilla, C.; Rigbolt, K. T. G.; Emdal, K. B.; Carraro, G.; Vernet, E.; Bekker-Jensen, D. B.; Streicher, W.; Wikström, M.; Sundström, M.; Bellusci, S.; Cavallaro, U.; Blagoev, B.; Olsen, J. V. Functional proteomics defines the molecular switch underlying FGF receptor trafficking and cellular outputs. *Mol. Cell* **2013**, *51*, 707–722. (37) Hunter, T. Tyrosine phosphorylation: thirty years and counting.

*Curr. Opin. Cell Biol.* **2009**, 21, 140–146.

(38) Ong, S.-E.; Blagoev, B.; Kratchmarova, I.; Kristensen, D. B.; Steen, H.; Pandey, A.; Mann, M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. *Mol. Cell. Proteomics* **2002**, *1*, 376–386.